Affordable Access

Publisher Website

HER2-positive breast cancer: trastuzumab, lapatinib and emerging therapies

Authors
Journal
Drug Discovery Today Therapeutic Strategies
1740-6773
Publisher
Elsevier
Volume
9
Identifiers
DOI: 10.1016/j.ddstr.2011.04.004
Disciplines
  • Biology
  • Medicine

Abstract

The discovery of the HER2 alteration in 20–25% of breast cancers has ushered in an era of molecularly targeted therapies. Targeting HER2 with antibody-based approaches, such as trastuzumab, or tyrosine kinase inhibitors, such as lapatinib, has yielded improvements in clinical outcomes. Nevertheless, mechanisms of actions underlying anti-HER2 therapies are incompletely understood, and drug resistance is frequently encountered in the clinic. In this review, standard-of-care and emerging therapies in HER2-positive breast cancer will be discussed, with a focus on strategies in late-phase clinical development.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

The emerging role of lapatinib in HER2-positive br...

on Current Oncology Reports January 2008

Beyond trastuzumab and lapatinib: new options for...

on American Society of Clinical O... 2013

A preclinical evaluation of the PI3K alpha/delta d...

on Breast Cancer Research and Tre... January 2015

Targeted therapies: Combined lapatinib and paclita...

on Nature Reviews Clinical Oncolo... June 2009
More articles like this..